# Valneva SE share price today (Valneva SE, VALN)

> Valneva SE's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VALN · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/valn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $5.63 (−35.4% in a year)
- Revenue (Jun 2026): $34.9 M (−27.7% on a year ago)
- Profit (Jun 2026): −$31.2 M
- Operating margin: −74.9% (−52.9 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Valneva SE share price today? Valneva SE's share price was $5.63 at the close on 4 November 2026. That is 16.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $11, and at that close it sat 13% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 1 year the share price moved −7% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Valneva SE pay? Valneva SE pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Valneva SE on? Valneva SE is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Valneva SE profitable? Valneva SE posted a net loss of $31.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $115 M. That loss is 89.3% of the quarter's revenue. The same quarter a year earlier lost $11.6 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Valneva SE make, and is it growing? Valneva SE reported $34.9 M of revenue in the Jun 2026 quarter, −27.7% on the same quarter a year earlier. Over 4 years it has grown −15.8% a year on average. The last full year, FY25, came in at $175 M. The last four reported quarters add to $143 M. FY25 revenue was $175 M, +3.0% on the year before. Recent pace: the last four quarters grew −27.7% on average, against −15.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −27.2%, against −2.6% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Valneva SE keep? Valneva SE's operating margin was −74.9% in the Jun 2026 quarter, 52.9 percentage points lower than the same quarter a year ago. Across 5 years it has been between −53.4% and 8.1%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −52.9 percentage points on the year while gross margin changed −52.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Valneva SE's profit turning into cash? Valneva SE's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $52.9 M of cash, against −$115 M of profit. After $4.4 M of spending on assets, free cash was −$57.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Valneva SE's cash go? Valneva SE does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $32.5 M on assets over the last 3 years. Averaged over those years that is 6.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $32.5 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Valneva SE's P/E ratio, and how does it compare with its own history? Valneva SE has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Valneva SE at 3.1× its FY25 revenue of $175 M. The P/E comes back here once profit turns positive. ## Is the Valneva SE business getting better or worse? Valneva SE's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Valneva SE earn on its capital? Valneva SE earned a ROE of −109% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −1,065%, a number that says nothing useful about the business. It comes from a −66.0% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −66.0% net margin × 0.44× asset turnover × 3.76× leverage (assets divided by equity) ≈ −109.2% on equity. The margin does its share; borrowing is a big part of it. ## Does Valneva SE have too much debt? Valneva SE has total debt of $210 M against shareholder equity of $81.1 M as of Jun 2026, so its debt is 2.59× its equity. Year by year, that ratio went from 0.67 in FY21 to 1.95 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Valneva SE shareholding pattern? We have no ownership or short-position figures for Valneva SE, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Valneva SE from balance-sheet trouble? For Valneva SE, the Z-score is −1.73. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.73 is inside the danger zone, so the balance sheet is a real risk. ## How does Valneva SE rank in its industry? There is no score against its industry: Valneva SE is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Valneva SE compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Valneva SE in size? Valneva SE is the 138th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Aclaris Therapeutics, Inc., Surrozen, Inc. and Puma Biotechnology, Inc. Just below it: Ovid Therapeutics Inc., Capricor Therapeutics, Inc. and Shattuck Labs, Inc. ### Biotechnology companies close in size

1. [Aclaris Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/acrs) $570 million
2. [Surrozen, Inc.](https://www.sectoralpha.in/us/stocks/srzn) $554 million
3. [Puma Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/pbyi) $552 million
4. Valneva SE $539 million
5. [Ovid Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/ovid) $535 million
6. [Capricor Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/capr) $519 million
7. [Shattuck Labs, Inc.](https://www.sectoralpha.in/us/stocks/sttk) $517 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Puma Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/pbyi) $528 million · Biotechnology
2. [Surrozen, Inc.](https://www.sectoralpha.in/us/stocks/srzn) $527 million · Biotechnology
3. Valneva SE $526 million
4. [Ennis, Inc.](https://www.sectoralpha.in/us/stocks/ebf) $525 million · Business Equipment & Supplies
5. [Hyster-Yale, Inc.](https://www.sectoralpha.in/us/stocks/hy) $524 million · Farm & Heavy Construction Machinery

## What else do people ask about Valneva SE? ### What were Valneva SE's latest quarterly results? Valneva SE reported revenue of $34.9 M and a net loss of $31.2 M for the Jun 2026 quarter. Earnings per share were −$0.17. The operating margin was −74.9%, 52.9 percentage points lower than a year earlier (as of 4 November 2026). ### What is Valneva SE's market cap? Valneva SE's market capitalisation is $539 M at a stock price of $5.63. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Valneva SE performing? Valneva SE's latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Valneva SE's stock price go up? This page does not forecast Valneva SE's stock price. What it shows instead: the stock price is $5.63. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Valneva SE in its business cycle? Valneva SE's FY25 operating margin was −46.7%, against a 5-year range of −53.4% to 8.1%: the low end of its own range, which is often where recoveries start. The latest quarter was −74.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Valneva SE story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Valneva SE a stock worth studying right now? What the numbers show: Valneva SE's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.